Debrasa · Deep brain targets for neurostimulation in affective disorders
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2017-05-01 → 2019-04-30
- EU contribution
- €187,420
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Deep brain targets for neurostimulation in affective disorders
Major depressive disorder and bipolar disorder are among the most serious psychiatric disorders with high prevalence and illness-related disability. Even with the multitude of methods used to treat depression, a significant portion of patients fails to respond, resulting in an estimated 1–3% prevalence of treatment-resistant depression (TRD). The most efficacious therapeutic alternative for TRD is an electroconvulsive therapy, which helps, however, in only about half of TRD cases. Deep brain stimulation (DBS), which is commonly used in neurological diseases, is now being applied as an alternative technique in the treatment of TRD. Nevertheless, the evidence for the efficacy and safety of DBS in depression is still weak and an optimal approach has yet to be established. Reliable biomarkers of brain abnormality in depression might help determine the suitability and efficacy of DBS treatment and personalized medicine might be the future outlook for DBS treatment of depression. Despite advanced neuroimaging methods developed in recent years, the pathophysiological mechanisms of depression remain poorly understood. The main goal of the project was to provide necessary knowledge about neurobiology of major depressive disorder. We studied the human brain to gain insights and collect information on objective biomarkers of depression. We found conspicuous characteristics of the brain networks affected by depression using electroencephalography. Better characterization of the pathophysiology of depression can improve diagnostics and consequently ameliorate treatment of depressive patients. Objective evaluation of the brain impairment in depression could be potentially useful for early identification of the illness that could help better management of the disease. Faster and more efficacious treatment would lead to faster reintegration of patients into the society, thus reducing economic burdens of the disease.
Data: CORDIS, © European Union
Project objective
Objective: The overarching goal of proposed project is to provide necessary knowledge about neurobiology of Major Depression Disorder (MDD), which would lead to higher efficacy in treatment of this affective disorder. The research objectives of the action are 1) identification of electrophysiological biomarkers of functional brain abnormities in treatment resistant depression (TRD) and 2) suggestion of novel targets for neurostimulation in patients with TRD.Methods: Twenty patients with major Depression Disorder (MDD) and 20 healthy controls will undergo a resting-state high-density EEG recording (HD-EEG). Microstate analysis will be performed to identify possible biomarkers of functional brain abnormity in MDD. Source activity will be obtained for regions of interest (ROI) using individual head model and a distributed linear inverse solution. Directed functional connectivity using Granger causal modelling will be applied to the source signals of ROI to identify abnormally interconnected nodes.Relevance: If new biomarkers of functional brain abnormity in MDD are identified, better characterisation of pathophysiology of depression will be made. If abnormal nodes of large-scale brain neuronal network are identified, new and individually specific targets for deep brain stimulation (DBS) will be suggested. These findings will support future implementation of highly individualised DBS treatment of TRD.
Original text from CORDIS.
Participants
- UNIVERSITE DE GENEVE · GeneveCoordinatorSwitzerland
Links
Data: CORDIS, © European Union